Dr. Vinay Prasad, the embattled top official at the Food and Drug Administration overseeing vaccines and biologics, has officially resigned from the agency following mounting pressure from conservatives, Trump allies, and a high-profile exposé led by activist Laura Loomer.
Prasad had held three powerful roles at the FDA — Chief Medical Officer, Chief Scientific Officer, and Director of the Center for Biologics Evaluation and Research (CBER) — before stepping down quietly on Tuesday.
Loomer Campaign: “A Wolf in Sheep’s Clothing at the FDA”
For weeks, Laura Loomer publicly accused Prasad of being a radical left-wing ideologue embedded deep in the Trump administration’s FDA. In a viral campaign, Loomer posted evidence of Prasad’s anti-Trump rhetoric, support for Bernie Sanders, and a policy record that stood in direct opposition to President Trump’s Make America Healthy Again (MAHA) agenda.
“This is no mere bureaucratic misstep,” Loomer warned. “It’s a catastrophic vetting failure that threatens to derail the America First healthcare revolution.”
Prasad’s Political History: Openly Anti-Trump
Investigations revealed that Prasad had:
-
Donated to Bernie Sanders in 2016
-
Voted for Biden in 2020 and declared he wanted him to win “more than anything”
-
Called Trump “perhaps the worst president in the history of the Republic”
-
Referred to Trump supporters and policies with mocking terms like “Orange Man”
-
Praised Dr. Anthony Fauci as “St. Anthony of Fauci”
His public comments included mocking Trump’s border policies, attacking Trump University, and referring to January 6 as a “terrible day” — aligning him squarely with the progressive wing of U.S. politics.
Controversy Over Gene Therapy Oversight
Prasad was also under fire for halting the distribution of Sarepta Therapeutics’ Elevidys, a gene therapy treatment for Duchenne muscular dystrophy, after reports linked it to several deaths. Critics, including former Sen. Rick Santorum, accused Prasad of waging a vendetta against the company and undermining medical innovation.
Prasad later reversed the restriction, but only for younger patients deemed at lower risk.
HHS: Prasad “Did Not Want to Be a Distraction”
The Department of Health and Human Services confirmed the resignation late Tuesday.
“Dr. Prasad did not want to be a distraction to the great work of the FDA in the Trump administration,” HHS spokesman Andrew Nixon said. “We thank him for his service.”
Prasad’s Fall Highlights Deep-State Concerns
The resignation marks a major victory for conservative watchdogs and Trump-aligned investigators who have warned of entrenched anti-Trump operatives inside federal agencies, especially in high-stakes regulatory bodies like the FDA.
Prasad was reportedly under consideration for an even more powerful role at the Center for Drug Evaluation and Research (CDER) — a move that could have made him more powerful than the FDA Commissioner himself.
Loomer Responds
“We exposed him. He’s out. This is how we fight the deep state,” Loomer posted Tuesday night. “One radical saboteur at a time.”
